Related by context. All words. (Click for frequent words.) 72 metastatic colorectal cancer 71 metastatic renal cell carcinoma 70 NSCLC 70 solid tumors 70 glioblastoma 68 renal cell carcinoma 68 multiple myeloma 67 gastrointestinal stromal tumor GIST 66 advanced NSCLC 66 gastrointestinal stromal tumors 66 HER2 positive breast cancer 65 metastatic breast cancer 65 melanoma 64 hormone refractory prostate cancer 64 glioblastoma multiforme GBM 64 mCRC 64 neuroendocrine tumors 64 chronic lymphocytic leukemia CLL 64 ipilimumab 64 metastatic disease 64 metastatic cancer 64 resistant ovarian cancer 64 soft tissue sarcoma 64 unresectable 63 cell lung cancer 63 lymphoma CTCL 63 HER2 positive 63 mRCC 63 IV metastatic melanoma 63 HER2 positive metastatic breast 63 gastrointestinal stromal tumors GIST 63 pancreatic adenocarcinoma 63 axitinib 63 metastatic colon cancer 63 GIST 63 castration resistant prostate cancer 63 pancreatic NET 63 B CLL 63 hepatocellular carcinoma 63 lupus nephritis 63 sorafenib 62 IMGN# 62 malignant pleural mesothelioma 62 leukemia AML 62 recurrent NSCLC 62 CLL 62 gemcitabine 62 voreloxin 62 metastatic kidney 62 hematologic malignancies 62 carcinoma 62 metastatic prostate cancer 62 follicular lymphoma 62 recurrent glioblastoma 62 liver metastases 62 relapsed refractory multiple myeloma 62 metastatic malignant melanoma 62 hepatocellular carcinoma HCC 62 myelofibrosis 62 refractory multiple myeloma 62 HRPC 61 relapsed multiple myeloma 61 refractory AML 61 malignant melanoma 61 brain metastases 61 superficial bladder cancer 61 IV melanoma 61 heavily pretreated 61 sunitinib 61 hematological cancers 61 Gleevec resistant 61 Glioblastoma Multiforme 61 chronic myeloid leukemia CML 61 medullary thyroid cancer 61 carfilzomib 61 pancreatic cancers 61 docetaxel chemotherapy 61 AP# [003] 60 recurrent GBM 60 metastatic RCC 60 recurrent ovarian cancer 60 leukemia ALL 60 OncoVEX GM CSF 60 temsirolimus 60 indolent NHL 60 cutaneous T cell 60 metastatic 60 tumors GIST 60 Hodgkin lymphoma NHL 60 sarcoma 60 Cotara 60 Vectibix 60 hepatocellular cancer 60 GvHD 60 acute myeloid leukemia AML 60 platinum refractory 60 Genasense ® 60 docetaxel 60 carcinoid tumors 60 recurrent glioblastoma multiforme 60 lymphomas 60 radiation sensitizer 60 cell lymphoma CTCL 60 adjuvant therapy 60 pancreatic carcinoma 60 leukemia CLL 59 chronic lymphocytic leukemia 59 phase IIb clinical 59 vandetanib 59 Amrubicin 59 HGS ETR1 59 sorafenib Nexavar ® 59 anticancer therapy 59 glufosfamide 59 tumors 59 erlotinib 59 acute myeloid leukemia 59 medulloblastoma 59 dasatinib Sprycel ® 59 chemotherapy regimens 59 metastatic cancers 59 malignancies 59 prostate cancer HRPC 59 vismodegib 59 gastric cancer 59 idiopathic pulmonary fibrosis IPF 59 perifosine 59 rituximab 59 temozolomide 59 vinorelbine 59 metastatic lung cancer 59 metastatic renal cell 59 Bezielle 59 metastatic GIST 59 T DM1 59 pralatrexate 59 amrubicin 59 refractory indolent non 59 liver cancer 59 metastatic colorectal 59 imatinib therapy 59 IV NSCLC 59 bortezomib 59 fallopian tube carcinoma 59 bevacizumab Avastin ® 59 cilengitide 59 gastrointestinal stromal tumor 59 Glioblastoma 58 Ceflatonin 58 bendamustine 58 T#I mutation 58 prostate cancer CRPC 58 multiple myeloma MM 58 TORISEL 58 imatinib resistant 58 heavily pretreated patients 58 FOLOTYN 58 mCRC patients 58 TTF Therapy 58 cancer mCRC 58 metastatic pancreatic cancer 58 relapsed ovarian cancer 58 bevacizumab Avastin 58 bevacizumab 58 mapatumumab 58 castrate resistant prostate cancer 58 non metastatic osteosarcoma 58 chlorambucil 58 differentiated thyroid 58 lung metastases 58 basal cell carcinoma BCC 58 relapsing remitting multiple sclerosis 58 alvespimycin 58 DLBCL 58 acute myelogenous leukemia AML 58 adecatumumab 58 tamibarotene 58 cetuximab Erbitux ® 58 metastases 58 topotecan 58 depsipeptide 58 soft tissue sarcomas 58 squamous cell carcinoma SCC 58 lymphoma 58 glioblastomas 58 dasatinib 58 sorafenib Nexavar 58 chronic myelogenous leukemia CML 58 GISTs 58 Acute Myeloid Leukemia AML 58 free survival PFS 58 CMV disease 58 refractory CTCL 57 non Hodgkin lymphoma 57 erlotinib Tarceva ® 57 chemotherapeutic agents 57 tivozanib 57 tyrosine kinase inhibitors 57 colorectal liver metastases 57 KRAS wild 57 Hodgkin Lymphoma 57 talactoferrin 57 EGFR inhibitors 57 hematological malignancies 57 metastatic bladder 57 PLX# 57 cetuximab 57 cell lymphoma 57 clofarabine 57 Acute Myelogenous Leukemia AML 57 monotherapy 57 anti angiogenic therapy 57 relapsed SCLC 57 cutaneous melanoma 57 chemoradiotherapy 57 ELACYT 57 refractory acute myeloid 57 Proxinium TM 57 CBLC# 57 imatinib 57 relapsing multiple sclerosis 57 tumor recurrence 57 chemotherapeutic agent 57 diabetic nephropathy 57 Allovectin 7 ® 57 XL# [003] 57 gemcitabine chemotherapy 57 advanced metastatic renal 57 sarcomas 57 refractory chronic myeloid 57 YONDELIS 57 dose cohorts 57 Hepatocellular Carcinoma HCC 57 relapsed refractory 57 lung tumors 57 bone metastases 57 pomalidomide 57 cytotoxic chemotherapy 57 TEMODAL 57 HuMax CD4 57 anticancer agents 57 IV malignant melanoma 57 Tamibarotene 57 prostate cancer mCRPC 57 ganetespib 57 pertuzumab 57 refractory NSCLC 57 metastatic CRC 57 IMA# 57 HCV infection 56 ixabepilone 56 Irinotecan 56 mTOR inhibitor 56 neoadjuvant therapy 56 cisplatin chemotherapy 56 trastuzumab 56 Li Fraumeni Syndrome 56 myelodysplastic syndrome MDS 56 systemic ALCL 56 cetuximab Erbitux 56 cutaneous T 56 metastatic castration resistant 56 recurrent glioblastoma multiforme GBM 56 acute leukemias 56 epithelial tumors 56 anaplastic thyroid cancer 56 BiovaxID 56 imatinib Gleevec 56 seminoma 56 diagnosed multiple myeloma 56 vemurafenib 56 advanced carcinoid 56 docetaxel Taxotere ® 56 huN# DM1 56 colorectal cancer 56 stage IIIB 56 dasatinib Sprycel 56 BAY #-# 56 vinca alkaloids 56 nonsmall cell lung cancer 56 Acute Radiation Syndrome ARS 56 cancers 56 imatinib Gleevec ® 56 antitumor activity 56 ADVEXIN 56 histone deacetylase HDAC inhibitor 56 malignant gliomas 56 Metastatic 56 pancreatic islet cell 56 myeloma 56 recurrent malignant glioma 56 evaluating tivozanib 56 Omacetaxine 56 Gleevec imatinib 56 tumor shrinkage 56 Sorafenib 56 advanced hepatocellular carcinoma 56 Nexavar sorafenib 56 refractory Hodgkin lymphoma 56 non squamous 56 Atiprimod 56 Folotyn 56 biologic therapy 56 HCV 56 olaparib 56 panobinostat 56 Afinitor 56 Acute Myeloid Leukemia 56 distant metastasis 56 enzastaurin 56 ovarian cancers 56 recurrent glioma 56 satraplatin Phase 56 metastatic malignant 56 colon carcinoma 56 CTCL 56 biliary tract cancer 56 carboplatin 56 neoadjuvant chemotherapy 56 relapsed leukemia 56 refractory PTCL 56 elacytarabine 56 SCCHN 56 Advexin 56 trabectedin 56 anti leukemic 56 malignancy 56 Chronic Lymphocytic Leukemia 56 gastrointestinal cancers 56 satraplatin 56 basal cell carcinoma 56 VEGF receptor inhibitor 56 prostate cancers 56 huC# DM4 56 resectable 56 osteosarcoma 56 picoplatin 56 CYT# potent vascular disrupting 56 bone metastasis 56 Nexavar 56 squamous cell cancer 56 Multiple Myeloma 56 unresectable liver cancer 56 non squamous NSCLC 56 REOLYSIN ® 56 OPAXIO 56 xenograft models 56 doxorubicin 55 carcinomas 55 locoregional 55 leukemia APL 55 metastatic HRPC 55 aflibercept 55 BRAF inhibitor 55 Fludara 55 gastric cancers 55 grade gliomas 55 ovarian cancer 55 ongoing Phase 1b 55 cell malignancies 55 carboplatin paclitaxel 55 Doxil ® 55 Reolysin 55 IRX 2 55 plus gemcitabine 55 complete remissions 55 refractory ovarian cancer 55 myeloproliferative disorders 55 metastatic breast 55 MT# MEDI 55 Azedra 55 MyVax R 55 prostate cancer AIPC 55 radiofrequency ablation RFA 55 VIDAZA 55 vascular disrupting agent 55 Cell Lung Cancer 55 MALT lymphoma 55 docetaxel Taxotere 55 eculizumab 55 standard chemotherapy regimen 55 SCH # 55 CHOP chemotherapy 55 Myelofibrosis 55 colorectal cancer liver metastases 55 glioblastoma multiforme 55 Alpharadin 55 Perifosine 55 angiogenesis inhibitor 55 AQ4N 55 decitabine 55 diffuse intrinsic pontine glioma 55 Allovectin 7 55 relapsed GBM 55 INCB# [002] 55 nab paclitaxel 55 acute myelogenous leukemia 55 obatoclax 55 refractory gout 55 Brentuximab Vedotin SGN 55 carcinoid cancer 55 follicular NHL 55 cediranib 55 BiTE antibody 55 OMAPRO 55 neuroendocrine cancers 55 AA amyloidosis 55 panitumumab 55 S. aureus infections 55 HER2 + 55 TACE 55 evaluable patients 55 pan HDAC inhibitor 55 medically inoperable 55 Tarceva 55 PARP inhibitors 55 severe sepsis 55 abiraterone 55 cetuximab Erbitux R 55 TACI Ig 55 ThermoDox R 55 androgen independent 55 TheraSphere 55 Tarceva erlotinib 55 gemcitabine carboplatin 55 lumiliximab 55 sunitinib Sutent 55 Azixa 55 randomized Phase 55 cytokine refractory 55 trastuzumab DM1 T DM1 55 Xanafide 55 Hedgehog Pathway Inhibitor 55 squamous cell carcinoma 55 Sutent 55 untreated metastatic melanoma 55 Torisel 55 chronic granulomatous disease 55 IMC A# 55 belinostat 55 microsphere therapy 55 Xcytrin 55 omacetaxine 55 dacarbazine 55 receptor tyrosine kinase inhibitor 55 interferon alfa 55 metastatic gastric 55 PEGylated interferon beta 1a 55 Rituxan rituximab 55 ThermoDox 55 INGN 55 adenocarcinoma 55 ADXS# 55 Annamycin 55 Oncophage 55 cytogenetic responses 55 investigational immunotherapy 55 antibody MAb 55 Crohn disease 55 rindopepimut 55 brain tumor glioblastoma multiforme 55 TREANDA 55 Metastatic melanoma 54 anticancer therapies 54 aHUS 54 Aflibercept 54 recurrent colorectal cancer 54 lupus 54 cell carcinoma 54 cervical carcinoma 54 acute myelogenous 54 pancreatic tumors 54 PXD# 54 lymphoid malignancies 54 colorectal cancers 54 irinotecan chemotherapy 54 refractory metastatic colorectal cancer 54 inoperable pancreatic cancer 54 Aplidin 54 pancreatic neuroendocrine tumors 54 imetelstat 54 Everolimus 54 pancreatic cancer 54 metastatic carcinoma 54 refractory chronic lymphocytic 54 anticancer agent 54 leiomyosarcoma 54 forodesine 54 chemotherapies 54 hematologic cancers 54 tyrosine kinase inhibitors TKIs 54 multi kinase inhibitor 54 Vicinium TM 54 imatinib mesylate 54 tanespimycin 54 Follicular Lymphoma 54 Allovectin 7 R 54 neuroblastoma 54 hypereosinophilic syndrome 54 Zolinza 54 stage IIIb 54 INCB# [001] 54 oritavancin 54 ependymoma 54 Hodgkin lymphoma 54 colorectal cancer CRC 54 histone deacetylase inhibitor 54 stage IIIB IV 54 ZYBRESTAT 54 chemoradiation 54 hepatitis C HCV 54 MEK inhibitors 54 metastatic liver 54 localized prostate cancer 54 Curaxin CBLC# 54 myelofibrosis polycythemia vera 54 Melanoma 54 trastuzumab DM1 54 Velcade bortezomib 54 pegylated liposomal doxorubicin 54 Erlotinib 54 cytarabine 54 CEQ# 54 azacitidine 54 Avastin 54 ThermoDox ® 54 prostate adenocarcinoma 54 Hsp# inhibition 54 tafamidis 54 HSCT 54 Hodgkin lymphoma HL 54 cell lymphomas 54 humanized anti 54 ASA# 54 allogeneic hematopoietic stem cell 54 acute promyelocytic leukemia 54 DIPG 54 SUTENT 54 radiation therapy SBRT 54 Gleevec imatinib mesylate 54 registrational trial 54 systemic lupus erythematosus 54 Follicular lymphoma 54 breast carcinomas 54 CA4P 54 PI3K inhibitor 54 Gliadel Wafer 54 hypercalcemia 54 Targretin 54 alkylating agents 54 CLL SLL 54 carcinoid 54 CYT# 54 Cloretazine 54 radioimmunotherapy 54 mitomycin 54 investigational monoclonal antibody 54 Vandetanib 54 Aurora kinase 54 Surgical resection 54 taxane therapy 54 Alocrest 54 cell carcinoma RCC 54 PSMA ADC 54 EpCAM 54 renal tumors 54 galiximab 54 acute lymphoblastic leukemia 54 distant metastases 54 bladder cancers 54 grade glioma 54 capecitabine Xeloda R 54 Burkitt lymphoma 54 hematologic disorders 54 malignant tumors 54 GVHD 54 Glioblastoma multiforme 54 GVAX 54 Phase Ib II 54 follicular non 54 zanolimumab 54 disease progression 54 Waldenstrom macroglobulinemia 54 Herceptin trastuzumab 54 Metastatic breast cancer 54 Yervoy 54 HER2 positive cancers 54 FOLFOX6 54 PKC# 54 Pralatrexate 54 relapsed CLL 54 tumor regression 54 sapacitabine 54 refractory CLL 54 cancer immunotherapies 54 MabCampath 54 commercialize deforolimus 54 breast tumors 54 plus dexamethasone 54 ToGA 54 Rituxan 54 metastatic lesions 54 Carboplatin 54 myelodysplastic syndromes MDS 54 Pemetrexed 54 lymphocytic leukemia 54 BrachySil TM 54 phenoxodiol 54 lapatinib 54 Vorinostat 54 L BLP# 54 Mantle Cell Lymphoma 54 chemotherapeutic 54 Enzastaurin 54 hormone refractory 54 breast carcinoma 54 Phase #b/#a clinical 54 demonstrated antitumor activity 54 sunitinib malate 54 squamous cell 54 carcinoma HCC 54 taxane chemotherapy 54 Glioblastoma multiforme GBM 54 Fludara ® 54 sorafenib tablets 54 K ras 54 metastatic castrate resistant 54 Chronic Lymphocytic Leukemia CLL 54 HCV infected 54 phase IIa clinical 54 assessing T DM1 54 unresectable stage 54 investigational compound 54 bleomycin 54 mycophenolate mofetil 54 standard chemotherapy regimens 53 Merkel cell carcinoma 53 TKI therapy 53 oral ridaforolimus 53 tyrosine kinase inhibitor 53 VELCADE 53 ovarian lung 53 BRIM2 53 pegfilgrastim 53 Panzem R NCD 53 myeloproliferative diseases 53 MGd 53 invasive bladder 53 Genasense 53 virotherapy 53 LBH# 53 doublet chemotherapy 53 post herpetic neuralgia 53 BRAF mutation 53 Amigal 53 thymoma 53 leukemias 53 non resectable 53 Kit CD# positive 53 gemcitabine Gemzar ® 53 immunomodulator 53 dacetuzumab 53 IIIB NSCLC 53 oral prodrug 53 PARP inhibitor 53 anti angiogenic agents 53 astrocytoma 53 milatuzumab 53 gastric adenocarcinoma 53 FOLFIRI 53 afatinib 53 chemotherapeutics 53 targeting CD# 53 tesetaxel 53 remission induction 53 familial amyloidotic polyneuropathy FAP 53 EGFR mutation positive 53 EGFR TKI 53 bladder cancer 53 hypophosphatasia 53 #D#C# 53 cancer 53 HGS# 53 T#I [002] 53 pazopanib 53 HER2 negative 53 gefitinib Iressa 53 pixantrone 53 EGFR expressing mCRC 53 CD# antibody [001] 53 farletuzumab 53 refractory APL 53 ara C 53 RG# [001] 53 docetaxel Taxotere R 53 DCVax R Brain 53 metastatic pancreatic 53 Carfilzomib 53 BRAF V# mutation 53 Alessandro Riva 53 Telcyta 53 MPS IVA 53 Acute myeloid leukemia 53 lapatinib Tykerb 53 pegylated interferon alpha 53 BRIM3 53 gefitinib 53 paclitaxel 53 anti TNF alpha 53 Chronic lymphocytic leukemia 53 visilizumab 53 uveal melanoma 53 HNSCC 53 GRN#L 53 irinotecan 53 TRISENOX 53 IL# PE#QQR 53 CUDC 53 EFAPROXYN 53 iniparib 53 surrogate endpoint 53 primary immunodeficiency PI 53 ALN TTR# 53 molecularly targeted 53 aflibercept VEGF Trap 53 sunitinib Sutent ® 53 metastatic ovarian cancer 53 T#I mutant 53 cholangiocarcinoma 53 ovarian carcinoma 53 elesclomol 53 immunotherapies 53 primary immunodeficiencies 53 entinostat 53 follicular lymphomas 53 myelofibrosis MF 53 patients evaluable 53 HCV SPRINT 53 alkylating agent 53 Seliciclib 53 paclitaxel carboplatin 53 skeletal metastases 53 Evoltra ® 53 figitumumab 53 bucindolol 53 acute lymphoblastic 53 investigational therapies 53 panitumumab Vectibix 53 VFEND 53 seliciclib 53 systemic lupus erythematosus SLE 53 Golimumab 53 cytoreduction 53 CR# vcMMAE 53 mycosis fungoides 53 acute ischemic stroke 53 prostate carcinoma 53 locoregional disease 53 hepatic metastases 53 EGFR 53 ponatinib 53 lintuzumab 53 Nexavar tablets 53 PNP inhibitor 53 Taxotere R 53 Ceflatonin R 53 HuCNS SC cells 53 tremelimumab 53 liposomal doxorubicin 53 bortezomib Velcade 53 cardiotoxicity 53 DCVax ® Brain 53 COU AA 53 adjuvant radiation 53 WT1 53 Phase 2b trial 53 lorvotuzumab mertansine 53 Evoltra TM 53 pediatric acute lymphoblastic 53 kidney urologic 53 BCG refractory 53 anthracyclines 53 MOZOBIL 53 KRAS mutant 53 follicular lymphoma FL 53 Taxotere 53 cell lymphoma PTCL 53 Idiopathic Pulmonary Fibrosis 53 papillary renal cell carcinoma 53 EOquin 53 calcineurin inhibitors 53 thalidomide Thalomid 53 virus HCV infection 53 ALN TTR 53 fluoropyrimidine 53 systemic fungal infections 53 indolent follicular non 53 castrate resistant 53 Halaven 53 unresectable locally advanced 53 HGS ETR2 53 CRPC 53 Cholangiocarcinoma 53 GBM tumors 53 diagnosed glioblastoma multiforme 53 brain tumors 53 noninfectious uveitis 53 intravesical instillation 53 PRTX 53 proteasome inhibitor 53 JMML 53 dirucotide 53 palifosfamide 53 cell lymphoma ALCL 53 hepatorenal syndrome 53 maribavir 53 Median survival 52 allogeneic stem cell 52 evaluable 52 Combidex 52 oral mucositis 52 relapsing remitting MS 52 Nexavar ® 52 SBRT 52 FTY# 52 immunomodulatory therapy 52 immunotherapy 52 KRAS status 52 Jevtana 52 Gleevec 52 Bortezomib 52 castration resistant 52 alveolar rhabdomyosarcoma 52 nilotinib 52 pleural mesothelioma 52 metastatic hormone refractory 52 interferon alpha 52 CoFactor 52 cisplatin resistant 52 Epratuzumab 52 nonmetastatic 52 cisplatin 52 IgG1 monoclonal antibody 52 Taxotere chemotherapy 52 AEG# 52 cutaneous squamous cell carcinoma 52 Hsp# inhibitor 52 Dacogen injection 52 thymic carcinoma 52 Gefitinib 52 ALCL 52 acute leukemia 52 monoclonal antibody 52 estramustine 52 premalignant 52 HuMax EGFr 52 bafetinib 52 biologic therapies 52 AMN# [001] 52 transitional cell carcinoma 52 irinotecan containing 52 Metastatic Colorectal Cancer 52 thymalfasin 52 anaplastic 52 Phase IIa clinical 52 Folfox 52 anti TNF 52 basiliximab 52 TYZEKA 52 MAbs 52 Gemzar ® 52 Revlimid 52 KRAS mutation 52 refractory CML 52 Ph + ALL 52 neratinib 52 basal cell carcinomas 52 romidepsin 52 relapsed AML 52 Neulasta ® 52 chemotherapy 52 Gorlin syndrome 52 abiraterone acetate 52 TG# [003] 52 onychomycosis 52 Provenge 52 myelodysplastic syndrome 52 essential thrombocythemia ET 52 invasive candidiasis 52 acute promyelocytic leukemia APL 52 FOLFOX4 52 KRAS mutant tumors 52 pemphigus vulgaris 52 personalized immunotherapy 52 BR.# 52 prostate tumors 52 nilotinib Tasigna ® 52 chronic HCV 52 prostate cancer CaP 52 HER2 52 ALN VSP 52 chronic myelogenous leukemia 52 MYDICAR ® 52 OXi# 52 refractory cutaneous T 52 Multiple Myeloma MM 52 tocilizumab 52 diagnosed GBM 52 HspE7 52 CANCIDAS 52 situ CIS 52 IIa trial 52 PI3K/Akt pathway inhibitor 52 myelodysplastic syndromes 52 Acute myeloid leukemia AML 52 Hepatitis C virus HCV 52 Mitoxantrone 52 localized renal 52 transplantation HCT 52 clinically localized prostate 52 anti EGFR antibody 52 rituximab Rituxan 52 EGFr 52 chronic hepatitis C. 52 pediatric malignancies 52 Rituximab 52 hematological diseases 52 5FU 52 prostate cancer PCa 52 retinoblastoma 52 HCV protease inhibitor 52 Uricase PEG 52 histologies 52 humanized monoclonal antibody 52 PROVENGE 52 Myelodysplastic Syndrome MDS 52 protein kinase inhibitor 52 EGFR mutations 52 Traficet EN 52 M Vax 52 Taxotere ® 52 renal carcinoma 52 idarubicin 52 zalutumumab 52 cintredekin besudotox 52 severe oral mucositis 52 eniluracil 52 anaplastic astrocytoma 52 FOLOTYN ® 52 adult chronic ITP 52 Cloretazine ® 52 invasive aspergillosis 52 CINTREDEKIN BESUDOTOX 52 epithelial ovarian cancer 52 anthracycline taxane 52 chemotherapy cisplatin 52 metastatic sarcoma 52 tumor 52 prostate tumor 52 luteinizing hormone releasing 52 fibrotic disease 52 acute GvHD 52 chronic HCV infection 52 PROSTVAC ® 52 Chemophase 52 trastuzumab Herceptin ® 52 immunotherapeutic 52 prostate cancer 52 EGFR targeting 52 NovoTTF 52 octreotide 52 Trastuzumab 52 melanomas 52 cisplatin gemcitabine 52 elotuzumab 52 Lymphoma 52 systemic lupus 52 Radiation Therapy SIRT 52 superficial basal cell carcinoma 52 Clolar 52 Defibrotide 52 operable breast cancer 52 EGFR mutation 52 ACZ# 52 teriflunomide 52 antiviral therapy 52 myeloablative 52 refractory colorectal cancer 52 Cloretazine R VNP#M 52 refractory angina 52 TTR amyloidosis 52 Phase III clinical 52 humanised monoclonal antibody 52 trastuzumab Herceptin R 52 refractory prostate cancer 52 chronic myeloid leukemia 52 JAK inhibitor 52 systemic scleroderma 52 uveitis